Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Subscribe To Our Newsletter & Stay Updated
